Guardant Health (NASDAQ: GH) reported Q4 EPS of ($0.64), $0.22 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $155.1 million versus the consensus estimate of $148.88 million.

GUIDANCE:

Guardant Health sees FY2024 revenue of $655-670 million, versus the consensus of $669.1 million. Representing growth of 16% to 19% compared to full year 2023, and full year 2024 non-GAAP gross margin excluding screening to be in the range of 60% to 62%. Guardant Health expects total non-GAAP operating expenses to be in the range of $740 to $750 million, representing a 1% to 3% increase compared to full year 2023, and free cash flow to be in the range of negative $320 to $330 million in 2024, an improvement compared to the full year 2023.

For earnings history and earnings-related data on Guardant Health (GH) click here.